- Report
- January 2024
- 172 Pages
Global
From €2105EUR$2,190USD£1,805GBP
- Report
- February 2019
- 156 Pages
Global
From €3061EUR$3,185USD£2,625GBP
€4373EUR$4,550USD£3,750GBP
- Report
- August 2022
- 30 Pages
Global
From €2643EUR$2,750USD£2,267GBP
- Report
- January 2022
- 205 Pages
Global
From €7209EUR$7,500USD£6,182GBP
- Report
- June 2018
- 103 Pages
Global
From €10568EUR$10,995USD£9,062GBP
- Report
- September 2021
- 105 Pages
Global
€3268EUR$3,400USD£2,802GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €481EUR$500USD£412GBP
- Report
- January 2019
- 35 Pages
Global
From €961EUR$1,000USD£824GBP
Xyrem is a central nervous system (CNS) drug used to treat narcolepsy, a sleep disorder characterized by excessive daytime sleepiness and sudden episodes of sleep. Xyrem is a brand name for sodium oxybate, a form of gamma-hydroxybutyrate (GHB). It is a sedative-hypnotic drug that works by increasing the amount of gamma-aminobutyric acid (GABA) in the brain, which helps to reduce the symptoms of narcolepsy. Xyrem is a Schedule III controlled substance and is only available through a restricted distribution program.
Xyrem is manufactured by Jazz Pharmaceuticals, a specialty pharmaceutical company based in Ireland. Other companies in the Xyrem market include Teva Pharmaceuticals, which markets a generic version of the drug, and Sunovion Pharmaceuticals, which markets a brand-name version of the drug. Show Less Read more
